Cupid Stock Hits Record High With 10,900% Return in Five Years; Shares Gain 23% Recently

The Quick Take

• Cupid share price has generated 10,900% returns over five years, delivering exceptional multibagger performance for long-term investors
• The stock gained 23% recently and hit a new record high, signaling continued momentum in what has been one of India's best-performing small-cap stocks
• Cupid operates in the healthcare products sector and its exceptional returns reflect both earnings growth and significant P/E multiple expansion over the period

Cupid's share price has generated 10,900% returns over a five-year period — a 110x gain that makes it one of India's most exceptional small-cap multibaggers — with the stock gaining 23% recently and hitting a new record high, per NDTV Profit. Cupid manufactures and exports condoms and oral rehydration salts under WHO and UN procurement contracts, serving global public health programs. The extraordinary return profile reflects both fundamental earnings compounding — as the company grew revenue and profit on expanding international contracts — and significant multiple expansion as institutional and retail investors discovered the quality of its business model.

The investment market context for Cupid's multibagger returns illustrates the asymmetric potential of India's small-cap segment. A Rs 1 lakh investment in Cupid five years ago would have grown to approximately Rs 1.1 crore — a return profile that drives retail investor interest in identifying the next similar story. Cupid's fundamental strength lies in its niche: WHO and UN supply chain contracts provide long-term revenue visibility at above-market pricing, and the company's quality certifications create genuine barriers to entry. However, at a record high after 10,900% returns, valuation risk increases — the key question is whether growth runway justifies current multiples.

The forward signals for Cupid are its annual report and investor presentations, which disclose the volume and tenure of WHO/UN procurement contracts that underpin revenue visibility. Monthly export data from DGFT for healthcare products will track Cupid's shipment trends. The primary risk is contract renewal: Cupid's business model is heavily dependent on continued WHO and UN procurement at existing volumes and pricing. The macro variable is global health spending — particularly UN and WHO budget allocations, which can be affected by geopolitical developments that redirect institutional health funding or change procurement priorities away from Cupid's product categories.

Synthesized from 1 source.